Citations

Clear

3942 citation(s) found for "To, Van".

Adenoviral gene transfer of a single‐chain IL‐23 induces psoriatic arthritis–like symptoms in NOD mice
Flores, Rafael R. , Carbo, Lana, Meter, Montina Van, Padilla, Consuelo M. López de , Zhao, Jing , Colangelo, Debora , Yousefzadeh, Negar , Angelini, Luise, Zhang, Lei , Pola, Enrico , Evans, Christopher H. , Gambotto, Andrea , Niedernhofer, Laura J. , Robbins, Paul D. , De Padilla, Consuelo M Lopez, Niedernhofer, Laura J , Robbins, Paul D , Zhang, Lei , Kim, Eun Young , Yousefzadeh, Matthew J., Vo, Nam

Mayo Clinic

The FASEB Journal | June 6, 2019 | Volume: 33 | Issue: 8 | Pages: 9505-9515

10.1096/fj.201900420r | PMID 31170010 Get It

ABSTRACT Previously, we demonstrated that intratumoral delivery of adenoviral vector encoding single‐chain (sc) IL‐23 (Ad.scIL‐23) was able to induce systemic antitumor immunity. Here, we examined the role of IL‐23 in diabetes in nonobese diabetic mice. Intravenous delivery of Ad.scIL‐23 did not accelerate the onset of hyperglycemia but instead resulted in the development of psoriatic arthritis. Ad.scIL‐23–treated mice developed erythema, scales, and thickening of the skin, as well as intervertebral disc degeneration and extensive synovial hypertrophy and loss of articular cartilage in the knees. Immunological analysis revealed activation of conventional T helper type 17 cells and IL‐17–producing γδ T cells along with a significant depletion and suppression of T cells in the pancreatic lymph nodes. Furthermore, treatment with anti–IL‐17 antibody reduced joint and skin psoriatic arthritis pathologies. Thus, these Ad.scIL‐23–treated mice represent a physiologically relevant model of psoriatic arthritis for understanding disease progression and for testing therapeutic approaches.—Flores, R. R., Carbo, L., Kim, E., Van Meter, M., De Padilla, C. M. L., Zhao, J., Colangelo, D., Yousefzadeh, M. J., Angelini, L. A., Zhang, L., Pola, E., Vo, N., Evans, C. H., Gambotto, A., Niedernhofer, L. J., Robbins, P. D. Adenoviral gene transfer of a single‐chain IL‐23 induces psoriatic arthritis–like symptoms in NOD mice. FASEB J. 33, 9505–9515 (2019). www.fasebj.org
National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive Bladder
Linder, Brian J. , Gebhart, John B. , Elliott, Daniel S. , Houten, Holly K. Van , Sangaralingham, Lindsey R. , Habermann, Elizabeth B. , Habermann, Elizabeth , Linder, Brian J

Mayo Clinic

Female Pelvic Medicine & Reconstructive Surgery | June 6, 2019 | Volume: 27 | Issue: 2 | Pages: e261-e266

10.1097/spv.0000000000000744 | PMID 31157717 Get It

Objective The aim of this study was to evaluate national patterns of care for women with overactive bladder (OAB) in an administrative data set and identify potential areas for improvement. Methods We performed an analysis using the OptumLabs Data Warehouse, which contains deidentified administrative claims data from a large national US health insurance plan. The study included women, older than 18 years, with a new OAB diagnosis from January 1, 2007, to June 30, 2017. We excluded those with an underlying neurologic etiology, with interstitial cystitis/painful bladder syndrome, were pregnant, or did not have continuous enrollment for 12 months before and after OAB diagnosis. Trends in management were assessed via the Cochran-Armitage test. Time to discontinuation among medications was compared using t test. Results Of 1.4 million women in the database during the study time frame, 60,246 (4%) were included in the study. Median age was 61 years [interquartile range (IQR), 50–73], and median follow-up was 2.6 years (IQR, 1.6–4.2). Overall, 37% were treated with anticholinergics, 5% with beta-3 agonists, 7% with topical estrogen, and 2% with pelvic floor physical therapy; 26% saw a specialist; and 2% underwent third-line therapy. Median time to cessation of prescription filling was longer for beta-3 agonists versus anticholinergics [median, 4.1 months (IQR, 1–15) vs 3.6 months (IQR, 1–10); P < 0.0001]. Use of third-line therapies significantly increased over the study time frame, from 1.1% to 2.2% ( P < 0.0001). Conclusions Most of the patients do not continue filling prescriptions for OAB medications, and a minority of patients were referred for specialty evaluation. Although third-line therapy use is increasing, it is used in a small proportion of women with OAB. Given these patterns, there may be underutilization of specialist referral and other OAB therapies.
The hepatic WASH complex is required for efficient plasma LDL and HDL cholesterol clearance
Wijers, Melinde, Zanoni, Paolo , Liv, Nalan , Vos, Dyonne , Jäckstein, Michelle Y., Smit, Marieke , Wilbrink, Sanne, Wolters, Justina C. , Veen, Ydwine T. van der, Huijkman, Nicolette, Dekker, Daphne, Kloosterhuis, Niels , Dijk, Theo H. van , Billadeau, Daniel D. , Kuipers, Folkert , Kuivenhoven, Jan Albert , Sluis, Bart van de , van de Sluis, Bart , Klumperman, Judith , Eckardstein, Arnold von

Mayo Clinic

JCI Insight | June 5, 2019 | Volume: 4 | Issue: 11 | Pages: No page available

10.1172/jci.insight.126462 | PMID 31167970 Get It

The evolutionary conserved Wiskott-Aldrich syndrome protein and SCAR homolog (WASH) complex is one of the crucial multiprotein complexes that facilitates endosomal recycling of transmembrane proteins. Defects in WASH components have been associated with inherited developmental and neurological disorders in humans. Here, we show that hepatic ablation of the WASH component Washc1 in chow-fed mice increases plasma concentrations of cholesterol in both LDLs and HDLs, without affecting hepatic cholesterol content, hepatic cholesterol synthesis, biliary cholesterol excretion, or hepatic bile acid metabolism. Elevated plasma LDL cholesterol was related to reduced hepatocytic surface levels of the LDL receptor (LDLR) and the LDLR-related protein LRP1. Hepatic WASH ablation also reduced the surface levels of scavenger receptor class B type I and, concomitantly, selective uptake of HDL cholesterol into the liver. Furthermore, we found that WASHC1 deficiency increases LDLR proteolysis by the inducible degrader of LDLR, but does not affect proprotein convertase subtilisin/kexin type 9–mediated LDLR degradation. Remarkably, however, loss of hepatic WASHC1 may sensitize LRP1 for proprotein convertase subtilisin/kexin type 9–induced degradation. Altogether, these findings identify the WASH complex as a regulator of LDL as well as HDL metabolism and provide in vivo evidence for endosomal trafficking of scavenger receptor class B type I in hepatocytes.
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma
Price, Katharine A. , Moore, Eric J. , Patel, Samir H. , Hinni, Michael L., García, Joaquín J. , Graner, Darlene E., Foster, Nathan R. , Ginos, Brenda, Neben-Wittich, M.A. , Garces, Yolanda I. , Chintakuntlawar, Ashish V. , Olsen, Kerry D., Abel, Kathryn M. Van , Kasperbauer, Jan L. , Janus, Jeffrey R. , Waddle, Mark R. , Miller, Robert C. , Shiraishi, Satomi , Foote, Robert L. , Neben-Wittich, Michelle, Waddle, Mark, Van Abel, Kathryn M , Chintakuntlawar, Ashish V , Daniel, J. , Price, Daniel L. , Shiraishi, Satomi

Mayo Clinic

Journal of Clinical Oncology | June 4, 2019 | Volume: 37 | Issue: 22 | Pages: 1909-1918

10.1200/jco.19.00463 | PMID 31163012 Get It

PURPOSE The purpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma could maintain historical rates for disease control while reducing toxicity and preserving swallow function and quality of life (QOL). PATIENTS AND METHODS MC1273 was a single-arm phase II trial testing an aggressive course of RT de-escalation after surgery. Eligibility criteria included patients with p16-positive oropharyngeal squamous cell carcinoma, smoking history of 10 pack-years or less, and negative margins. Cohort A (intermediate risk) received 30 Gy delivered in 1.5-Gy fractions twice per day over 2 weeks along with 15 mg/m 2 docetaxel once per week. Cohort B included patients with extranodal extension who received the same treatment plus a simultaneous integrated boost to nodal levels with extranodal extension to 36 Gy in 1.8-Gy fractions twice per day. The primary end point was locoregional tumor control at 2 years. Secondary end points included 2-year progression-free survival, overall survival, toxicity, swallow function, and patient-reported QOL. RESULTS Accrual was from September 2013 to June 2016 (N = 80; cohort A, n = 37; cohort B, n = 43). Median follow-up was 36 months, with a minimum follow-up of 25 months. The 2-year locoregional tumor control rate was 96.2%, with progression-free survival of 91.1% and overall survival of 98.7%. Rates of grade 3 or worse toxicity at pre-RT and 1 and 2 years post-RT were 2.5%, 0%, and 0%. Swallowing function improved slightly between pre-RT and 12 months post-RT, with one patient requiring temporary feeding tube placement. CONCLUSION Aggressive RT de-escalation resulted in locoregional tumor control rates comparable to historical controls, low toxicity, and little decrement in swallowing function or QOL.
Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
Yang, Hayang , Veldtman, Gruschen , Bouma, Berto J. , Budts, Werner , Niwa, Koichiro , Meijboom, Folkert J., Egbe, Alexander C. , Schwerzmann, Markus , Broberg, Craig S. , Buber, Jonathan , Tsai, Shane, Post, Martijn C. , Mulder, Barbara J.M. , Egbe, Alexander Chima, Schwerzmann, Markus , Scognamiglio, Giancarlo , Morissens, Marielle , Polyzois, Ioannis , Greutmann, Matthias , Dijk, Arie P.J. van , Aboulhosn, Jamil , Bouma, Berto J

Mayo Clinic

Open Heart | June 4, 2019 | Volume: 6 | Issue: 1 | Pages: e000985

10.1136/openhrt-2018-000985 | PMID 31245011 Get It

Background In Fontan patients with atrial arrhythmias (AA), non-vitamin K antagonist oral anticoagulants(NOACs) have a class III recommendation according to the Pediatric & Congenital Electrophysiology Society (PACES)/Heart Rhythm Society (HRS) guideline in 2014, due to lack of data on outcomes as opposed to evidence of harm. To address this gap in data, we investigated the safety and efficacy of NOACs in adults with a Fontan circulation in a worldwide study. Methods This is an international multicentre prospective cohort study, using data from the NOTE ( n on-vitamin K antagonist o ral anticoagulants for t hrombo e mbolic prevention in patients with congenital heart disease) registry. The study population comprised consecutive adults with a Fontan circulation using NOACs. Follow-up took place at 6 months and yearly thereafter. The primary endpoints were thromboembolism and major bleeding. Secondary endpoint was minor bleeding. Results From April 2014 onward, 74 patients (mean age 32±10 years (range 18–68), 54% male) with a Fontan circulation using NOACs were included. During a median follow-up of 1.2 (IQR 0.8–2.0) years, three thromboembolic events (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) and three major bleedings (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) occurred in five atriopulmonary Fontan and one total cavopulmonary connection Fontan patients with AA. Fifteen patients experienced minor bleeding episodes (15.8 per 100 patient-years (95% CI 9.1 to 25.2)). In patients (n=37) using vitamin K antagonists (VKAs) prior to the initiation of NOAC, annual incidence of historical thromboembolic events and major bleeding were 2.4% (95% CI 0.4% to 7.4%) (n = 2) and 1.2% (95% CI 0.7% to 5.1%) (n = 1), respectively. Conclusions In this review of the largest Fontan cohort using NOACs with prospective follow-up, NOACs appear to be well tolerated and their efficacy and safety during short-term follow-up seem comparable to VKAs. Longer term data are required to confirm these promising short-term results.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx
André, Fabrice , Ismaila, Nofisat , Henry, N. Lynn , Somerfield, Mark R. , Hammond, M. Elizabeth, Kuderer, Nicole M. , Liu, Minetta C. , Poznak, Catherine Van , Henry, N Lynn , André, Fabrice , Bast, Robert C. , Barlow, William E. , Collyar, Deborah , Wolff, Antonio C. , Stearns, Vered

Mayo Clinic

Journal of Clinical Oncology | May 31, 2019 | Volume: 37 | Issue: 22 | Pages: 1956-1964

10.1200/jco.19.00945 | PMID 31150316 Get It

PURPOSE This focused update addresses the use of Onco type DX in guiding decisions on the use of adjuvant systemic therapy. METHODS ASCO uses a signals approach to facilitate guideline updating. For this focused update, the publication of the Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority of endocrine therapy alone versus chemoendocrine therapy for invasive disease–free survival in women with Onco type DX scores provided a signal. An expert panel reviewed the results of TAILORx along with other published literature on the Onco type DX assay to assess for evidence of clinical utility. UPDATED RECOMMENDATIONS For patients with hormone receptor–positive, axillary node–negative breast cancer whose tumors have Onco type DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years. For patients 50 years of age or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30. Additional information can be found at www.asco.org/breast-cancer-guidelines .
Heritability in genetic heart disease: the role of genetic background
Jansweijer, Joeri A. , Spaendonck‐Zwarts, Karin Y. van, Tanck, Michael W.T. , Tintelen, J. Peter van , Christiaans, Imke , Smagt, Jasper J. van der , Vermeer, Alexa M.C. , Bos, J. Martijn , Moss, Arthur J. , Swan, Heikki, Priori, Silvia G. , Rydberg, Annika , Tfelt‐Hansen, Jacob , Ackerman, Michael J. , Olivotto, Iacopo , Berg, Maarten P. van den , WILDE, ARTHUR A. M., Pinto, Yigal M. , van Tintelen, J Peter , Olivotto, Iacopo , Bos, Johan M , Tanck, Michael , Tfelt-Hansen, Jacob , van den Berg, Maarten P , Charron, Philippe , Gimeno, Juan Ramón , Priori, Silvia

Mayo Clinic

Open Heart | May 29, 2019 | Volume: 6 | Issue: 1 | Pages: e000929

10.1136/openhrt-2018-000929 | PMID 31245010 Get It

Background Mutations in genes encoding ion channels or sarcomeric proteins are an important cause of hereditary cardiac disease. However, the severity of the resultant disease varies considerably even among those with an identical mutation. Such clinical variation is often thought to be explained largely by differences in genetic background or ‘modifier genes’. We aimed to test the prediction that identical genetic backgrounds result in largely similar clinical expression of a cardiac disease causing mutation, by studying the clinical expression of mutations causing cardiac disease in monozygotic twins. Methods We compared first available clinical information on 46 monozygotic twin pairs and 59 control pairs that had either a hereditary cardiomyopathy or channelopathy. Results Despite limited power of this study, we found significant heritability for corrected QT interval (QTc) in long QT syndrome (LQTS). We could not detect significant heritability for structural traits, but found a significant environmental effect on thickness of the interventricular septum in hypertrophic cardiomyopathy. Conclusions Our study confirms previously found robust heritability for electrical traits like QTc in LQTS, and adds information on low or lacking heritability for structural traits in heritable cardiomyopathies. This may steer the search for genetic modifiers in heritable cardiac disease.
Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis
López‐Chiriboga, A. Sebastian , Stavern, Gregory Van , Pittock, Sean J. , Fryer, Jim, Bhatti, M. Tariq , Chen, John J. , Pittock, S J , Chen, John J , Flanagan, Eoin P.

Mayo Clinic

Neuro-Ophthalmology | May 29, 2019 | Volume: 44 | Issue: 1 | Pages: 1-4

10.1080/01658107.2019.1607883 | PMID 32076441 Get It

Long-term survival of adjuvant high-dose (HDC) vs weekly cisplatin (WC) for human papilloma-virus (HPV) and non-HPV head and neck squamous cell carcinoma (HNSCC).
Price, Katharine A. , Foote, Robert L. , Garces, Yolanda I. , Neben-Wittich, M.A. , Moore, Eric J. , Kasperbauer, Jan C., Janus, Jeffrey R. , Geiger, J.L. , Chintakuntlawar, Ashish V. , Daniel, J. , Price, Daniel L. , Abel, Kathryn M. Van

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 6071-6071

10.1200/jco.2019.37.15_suppl.6071 Get It

6071 Background: Phase III data suggests a benefit of HDC in the adjuvant setting, but the effect of HDC and WC on long term survival and for HPV+ HNSCC is unknown. Methods: Data from a published retrospective study (Geiger Oral Onc 2013) of HDC vs WC in resected HNSCC was updated. Overall survival (OS) and recurrence-free survival (RFS) was assessed by Kaplan-Meier method for all pts and by HPV status. Multivariate analyses were performed to assess impact of HPV status, smoking, age, HDC vs WC, and cumulative cisplatin dose ( < 200mg/m2 vs ≥200 mg/m2). Results: 51 patients (pts) received HDC and 53 WC. Median follow-up was 8.7 yrs (0.8-13.7). For the whole cohort, HDC had significantly improved OS over WC (p = 0.0095; 5- and 10-yr OS 84% and 80% vs 72% and 60%). No OS benefit for HDC was seen in pts with HPV+HNSCC (5- and 10-yr OS 90% and 87% for HDC and 81% and 81% for WC; p = 0.51). For HPV-negative HNSCC, OS had borderline significance with HDC vs WC (5- and 10-yr OS 73% and 68% vs 65% and 44%; p = 0.06). For the whole cohort, there was no difference in 5- and 10-yr RFS (78% and 74% for HDC vs 72% and 62% for WC; p = 0.32). When analyzed by HPV status, there was no difference in RFS with HDC or WC for either HPV+ (p = 0.43) or HPV-negative HNSCC (p = 0.97). On multivariate analyses of OS for all pts, only HPV status was significant (p = 0.0011; HR 0.27, CI 0.12-0.62). For HPV+ HNSCC, there was no significant predictor of OS. For non-HPV HNSCC, the benefit of HDC approached significance with a decreased risk of death (HR 0.38; p = 0.07). For all pts, those who received ≥200mg/m2 had significantly improved OS (5-yr 90% vs 72% and 10-yr 86% vs 61%; p = 0.004). By HPV status, cumulative dose had no significant effect on OS. Conclusions: OS is better with HDC and with cumulative dose > 200 mg/m2 in unselected patients. The benefit of cisplatin is likely higher for non-HPV HNSCC. A difference in OS with no difference in RFS suggests non cancer-related causes of death in the WC cohort. Ability to receive HDC could be a surrogate marker of comorbidity. [Table: see text]
Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization.
Horn, Robert Asa, Tannenbaum, Daniel, Overman, Michael J. , Rogers, Jane E. , Morris, Van K. , Johnson, Benny , Parseghian, Christine Megerdichian , Kopetz, Scott , Eng, Cathy , Raghav, Kanwal , Dasari, Arvind , Rogers, Jane E

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e15055-e15055

10.1200/jco.2019.37.15_suppl.e15055 Get It

e15055 Background: An increasing number of pt and tumor c have predictive and prognostic implications in mCRC. However, there is no consensus on their reporting in trial results. Methods: Pt c and SF from 136 phase III trials of systemic therapies (Rx) in mCRC published between 1988 and 2018 (68,326 pts) were collected. Trials were also grouped per publication date (G1: 1988-97; G2: 98 – 2007; G3: 08-18). Patterns of reporting and trends across G were evaluated. Results: Pt c consistently reported were performance status, PS (98.5%), age (92.6%) and gender (90.4%); race (20.6%) & weight/BMI/BSA were not (13.2%). Tumor c frequently reported were metastatic (met) spread (70.6%) while time intervals related to disease course (25%) and synchronous met vs not (19.1%) were omitted. Of note, primary site was largely reported as colon vs rectum (69%) and sidedness or anatomical location was discernable only in 10.3%. Prior Rx reporting focused on chemo (58.5%) with radiation and surgery and reported in 34% & 28.7%. Reporting of prognostic factors was variable and limited: histology grade CEA, alk phos, LDH (range 10.3-15.4%). Only 11.8% of trials reported genomic factors - KRAS MT was included in all with BRAF MT in 4.4%. Of 140 trials used for SF analysis, 115 had ≥ 1 (range 1-7). Common SF were PS (60%), geography /institution (55.7%). Prior Rx (27%), met spread (24.3%) were sometimes used while primary site (7.8%), genomic factors (6.1%) rarely were. Trends across G are per Table. Conclusions: There is marked inconsistency in pt c & SF reporting in mCRC trials. Consensus guidelines will aid in standardization of trial interpretation and future meta-analyses; and will need to be updated based on emerging data. [Table: see text]